These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 15258401)

  • 41. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
    Lu D; Vince R
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5614-9. PubMed ID: 17822899
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crystallization and preliminary neutron diffraction studies of HIV-1 protease cocrystallized with inhibitor KNI-272.
    Matsumura H; Adachi M; Sugiyama S; Okada S; Yamakami M; Tamada T; Hidaka K; Hayashi Y; Kimura T; Kiso Y; Kitatani T; Maki S; Yoshikawa HY; Adachi H; Takano K; Murakami S; Inoue T; Kuroki R; Mori Y
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2008 Nov; 64(Pt 11):1003-6. PubMed ID: 18997326
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Conformational preferences of proline analogues with different ring size.
    Jhon JS; Kang YK
    J Phys Chem B; 2007 Apr; 111(13):3496-507. PubMed ID: 17388495
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Structural insights into the mechanisms of drug resistance in HIV-1 protease NL4-3.
    Heaslet H; Kutilek V; Morris GM; Lin YC; Elder JH; Torbett BE; Stout CD
    J Mol Biol; 2006 Mar; 356(4):967-81. PubMed ID: 16403521
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
    J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tryptophan rich peptides: influence of indole rings on backbone conformation.
    Mahalakshmi R; Sengupta A; Raghothama S; Shamala N; Balaram P
    Biopolymers; 2007; 88(1):36-54. PubMed ID: 17091496
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Convergent chemical synthesis and crystal structure of a 203 amino acid "covalent dimer" HIV-1 protease enzyme molecule.
    Torbeev VY; Kent SB
    Angew Chem Int Ed Engl; 2007; 46(10):1667-70. PubMed ID: 17397076
    [No Abstract]   [Full Text] [Related]  

  • 49. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A potent HIV protease inhibitor identified in an epimeric mixture by high-resolution protein crystallography.
    Geremia S; Demitri N; Wuerges J; Benedetti F; Berti F; Tell G; Randaccio L
    ChemMedChem; 2006 Feb; 1(2):186-8. PubMed ID: 16892350
    [No Abstract]   [Full Text] [Related]  

  • 51. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
    Specker E; Böttcher J; Brass S; Heine A; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
    ChemMedChem; 2006 Jan; 1(1):106-17. PubMed ID: 16892342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
    J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
    Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
    Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
    Ami E; Nakahara K; Sato A; Nguyen JT; Hidaka K; Hamada Y; Nakatani S; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4213-7. PubMed ID: 17537628
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of novel HIV-1 protease inhibitors incorporating oxyindoles as the P2'-ligands.
    Ghosh AK; Schiltz G; Perali RS; Leshchenko S; Kay S; Walters DE; Koh Y; Maeda K; Mitsuya H
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1869-73. PubMed ID: 16480871
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains.
    Wannberg J; Sabnis YA; Vrang L; Samuelsson B; Karlén A; Hallberg A; Larhed M
    Bioorg Med Chem; 2006 Aug; 14(15):5303-15. PubMed ID: 16621572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor.
    Clemente JC; Govindasamy L; Madabushi A; Fisher SZ; Moose RE; Yowell CA; Hidaka K; Kimura T; Hayashi Y; Kiso Y; Agbandje-McKenna M; Dame JB; Dunn BM; McKenna R
    Acta Crystallogr D Biol Crystallogr; 2006 Mar; 62(Pt 3):246-52. PubMed ID: 16510971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Solvent polarity controls the helical conformation of short peptides rich in Calpha-tetrasubstituted amino acids.
    Bellanda M; Mammi S; Geremia S; Demitri N; Randaccio L; Broxterman QB; Kaptein B; Pengo P; Pasquato L; Scrimin P
    Chemistry; 2007; 13(2):407-16. PubMed ID: 17154197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and activity of tetrapeptidic HTLV-I protease inhibitors possessing different P3-cap moieties.
    Zhang M; Nguyen JT; Kumada HO; Kimura T; Cheng M; Hayashi Y; Kiso Y
    Bioorg Med Chem; 2008 May; 16(10):5795-802. PubMed ID: 18400502
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Structure, dynamics and solvation of HIV-1 protease/saquinavir complex in aqueous solution and their contributions to drug resistance: molecular dynamic simulations.
    Wittayanarakul K; Aruksakunwong O; Sompornpisut P; Sanghiran-Lee V; Parasuk V; Pinitglang S; Hannongbua S
    J Chem Inf Model; 2005; 45(2):300-8. PubMed ID: 15807491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.